Academic Journal
Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
| Title: | Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients |
|---|---|
| Authors: | Laila König, Matthias F. Häfner, Sonja Katayama, Stefan A. Koerber, Eric Tonndorf-Martini, Denise Bernhardt, Bastian von Nettelbladt, Fabian Weykamp, Philipp Hoegen, Sebastian Klüter, Matthew S. Susko, Jürgen Debus, Juliane Hörner-Rieber |
| Source: | Radiation Oncology, Vol 15, Iss 1, Pp 1-9 (2020) |
| Publisher Information: | BMC, 2020. |
| Publication Year: | 2020 |
| Collection: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Adrenal gland metastases, Stereotactic body radiotherapy (SBRT), Image-guided radiotherapy, Oligometastases, Oligoprogression, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Abstract Introduction Local ablative treatment strategies are frequently offered to patients diagnosed with oligometastatic disease. Stereotactic body radiotherapy (SBRT), as ablative treatment option, is well established for lung and liver metastases, whereas for isolated adrenal gland metastases the level of evidence is scarce. Material and methods This single-institution analysis of oligometastatic or oligoprogressive disease was limited to patients who received SBRT to adrenal metastasis between 2012 and 2019. Patient, tumor, treatment characteristics, and dosimetric parameters were analyzed for evaluation of their effect on survival outcomes. Results During the period of review 28 patients received ablative SBRT to their adrenal gland metastases. Most common primary tumors were non-small cell lung cancers (46%) with most patients diagnosed with a single adrenal gland metastasis (61%), which occurred after a median time of 14 months. SBRT was delivered to a median biological effective dose at α/β of 10 (BED10) of 75 Gy (range: 58–151 Gy). Median gross tumor volume (GTV) and median planning target volume (PTV) were 42 and 111 mL, respectively. The homogeneity and conformity indices were 1.17 (range: 1.04–1.64) and 0.5 (range: 0.4.0.99), respectively, with the conformity index being affected by dose restrictions to organs at risk (OARs) in 50% of the patients. Overall response rate based on RECIST criteria was 86% (CR = 29%, PR = 57%) with 2-year local control (LC) of 84.8%, 2-year progression-free survival (PFS) of 26.3%, and 1-and 2-year overall survival (OS) of 46.6 and 32.0%, respectively. During follow up, only two local recurrences occurred. A trend for superior LC was seen if BED10 was ≥75Gy (p = 0.101) or if the PTV was |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1748-717X |
| Relation: | https://doaj.org/toc/1748-717X |
| DOI: | 10.1186/s13014-020-1480-0 |
| Access URL: | https://doaj.org/article/5a529de62e184c4a87a347a949354d7d |
| Accession Number: | edsdoj.5a529de62e184c4a87a347a949354d7d |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 1748717X |
|---|---|
| DOI: | 10.1186/s13014-020-1480-0 |
| Published in: | Radiation Oncology |
| Language: | English |